C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...

Injection drug use is both a potent risk factor for incarceration and the primary transmission route for hepatitis C virus (HCV) infections. Combining HCV testing and treatment in jails with ...

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...

MANCHESTER and LONDON, England — Alison Starkie spends her days tracking down people who need testing or treatment for hepatitis C, especially those who are unhoused or actively using drugs. Starkie, ...

Research from RAND and the Terner Center, with support from the Cooper Housing Institute, demonstrates the effectiveness of the Housing Choice Voucher program and offers solutions to increase program ...

AMARILLO, Texas (KAMR/KCIT) — Officials with the Amarillo Housing Authority announced that it will begin accepting pre-applications for its housing vouchers with a waitlist lottery. AHA said ...

Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...